Related Experiment Video
Updated: Nov 29, 2025
08:14
A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
8.4K
PCSK9 Causes MHC Class I Lysosomal Degradation to Promote Tumor Growth
Cancer Discovery
|November 21, 2020
Abstract:
The efficacy of anti-PD-1 treatment was enhanced by deletion of Pcsk9 or PCSK9 inhibition in mice.
Insights
Deleting Pcsk9 or inhibiting PCSK9 in mice significantly boosted the effectiveness of anti-PD-1 cancer treatments. This finding suggests a new strategy for improving immunotherapy outcomes.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- Immune checkpoint inhibitors, such as anti-PD-1 therapies, have revolutionized cancer treatment.
- However, a significant portion of patients do not respond to these therapies, necessitating strategies to enhance their efficacy.
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) is primarily known for its role in cholesterol metabolism.
Purpose of the Study:
- To investigate the impact of Proprotein convertase subtilisin/kexin type 9 (PCSK9) deletion or inhibition on the efficacy of anti-programmed cell death protein 1 (PD-1) therapy in a preclinical mouse model.
- To explore potential mechanisms underlying the observed effects of PCSK9 modulation on anti-tumor immunity.
Main Methods:
- Utilized a mouse model for cancer immunotherapy studies.
- Administered anti-PD-1 antibodies to mice.
- Genetically deleted the *Pcsk9* gene or pharmacologically inhibited PCSK9 in mice.
- Assessed tumor growth and immune cell infiltration in response to treatment.
Main Results:
- Deletion of *Pcsk9* or PCSK9 inhibition significantly enhanced the therapeutic efficacy of anti-PD-1 treatment in mice.
- Tumor growth was markedly reduced in mice with *Pcsk9* deletion or PCSK9 inhibition compared to control groups.
- Preliminary analyses suggest alterations in the tumor microenvironment contributing to enhanced immune response.
Conclusions:
- Modulating PCSK9 levels, through genetic deletion or pharmacological inhibition, represents a promising strategy to improve the effectiveness of anti-PD-1 immunotherapy.
- PCSK9 may play an underappreciated role in regulating anti-tumor immunity.
- Further research is warranted to translate these findings into clinical applications for cancer patients.
Related Concept Videos
02:23Abnormal Proliferation
4.9K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
03:03mTOR Signaling and Cancer Progression
4.2K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.2K
01:15Receptor Downregulation in MVBs
2.6K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.6K
01:22Lysosomal Hydrolases
4.2K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.2K
01:06Induced Pluripotent Stem Cells
4.9K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.9K
00:50Anaphase Promoting Complex
3.2K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.2K